AstraZeneca (AZN) Reports Results of BRILINTA Sub-Study at ACC 12

AstraZeneca (NYSE: AZN) today announced results from a sub-analysis of the PLATO genetic sub-study that evaluated the impact of poor metabolizers of clopidogrel. Data suggests results were consistent with the overall outcome of the PLATO study, with BRILINTA (ticagrelor) compared to clopidogrel, even after poor clopidogrel metabolizers were excluded. Results of this sub-analysis were presented today at the American College of Cardiology Scientific Sessions (ACC), in Chicago, Ill.

A poor metabolizer to clopidogrel is defined as a patient with two loss-of-function (LOF) CYP2C19 alleles, one of the main genetic factors affecting the conversion of clopidogrel to its active form. In this sub-analysis, 10,285 DNA samples from patients in the PLATO trial, (which randomized 18,624 ACS patients to ticagrelor or clopidogrel for 6 – 12 months), underwent CYP2C19 genotyping for wildtype (*1); LOF alleles *2, *3, *4, *5, *6, *7, & *8; and gain of function allele *17. Patients with any combination of two LOF alleles were denoted as a poor metabolizer. Analysis of PLATO primary efficacy and safety outcomes were conducted after excluding poor metabolizers from both treatment groups.

Below are the results from the sub-analysis:

• After removal of poor metabolizers (121 of 5,137 ticagrelor patients; 125 of 5,148 clopidogrel patients), the remaining non-poor metabolizers cohort (n=10,039) showed a reduction in the primary endpoint consistent with overall results of the PLATO study with ticagrelor compared to clopidogrel at 12 months (8.8% vs 10.4 %; hazard ratio [HR] 0.85, 95% confidence interval 0.74-0.96, P=0.01)
  
  
• Rates of total major bleeding at 12 months did not differ between treatment groups, 10.7%; non-CABG major bleeding trended higher with ticagrelor (4.0%) than with clopidogrel (3.3%)
  
  
• Ticagrelor similarly reduced the primary endpoint in the poor metabolizers group at 12 months (8.8% vs 9.7%, HR=0.87), although there were only 22 events in this very small subgroup of patients

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small ce
• Westlake Corp adds dual listing on NYSE Texas exchange
• Greenland approves rare earths license transfer to Greenland Mines